Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia.
- Author:
Qin LI
1
;
Ming HONG
;
Si-Xuan QIAN
;
Run ZHANG
;
Wen-Yi SHENG
;
Han-Xin WU
;
Hua LU
;
Hong-Xia QIU
;
Wei XU
;
Jian-Yong LI
Author Information
1. Department of Hematology, The First Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cytarabine;
administration & dosage;
therapeutic use;
Female;
Granulocyte Colony-Stimulating Factor;
therapeutic use;
Hematopoietic Stem Cell Mobilization;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
therapy;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
methods;
Transplantation, Autologous;
Vidarabine;
administration & dosage;
analogs & derivatives;
therapeutic use;
Young Adult
- From:
Journal of Experimental Hematology
2009;17(5):1335-1338
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the effect of FLAG consolidatory therapy on peripheral blood stem cell (PBSC) mobilization in patients with acute myelogenous leukemia (AML) for autologous PBSC transplantation. A total of 15 AML patients were enrolled in this study. 10 patients were male, and 5 were female, with ages ranging from 14 to 51 (median 36) years. Out of 15 patients 13 were newly diagnosed, and 2 were refractory/relapsed AML. All patients were consolidated with FLAG regimen which including fludarabine 50 mg/d, days 1-5; Ara-C 2 g/(m2.d), days 1-5; G-CSF 300 microg/d, injection subcutaneously starting 24 hours before Ara-C and continuing until neutrophil count exceeding 1.0x10(9)/L. The harvest of the stem cells was performed after hematologic recovery from the second or third course of FLAG consolidation, or mobilized by high dose etoposide (1.6 g/m2). The results showed that among 15 patients scheduled for PBSC harvest, 11 (73.3%) harvested a median of 3.52x10(6)/kg CD34+ cells (range 2.2-4.6) and underwent autologous transplantation, while the minimal number of CD34+ cells could not be reached in the remaining 4 patients. It is concluded that the FLAG regimen is effective and well-tolerated treatment as consolidation regimen in AML, which does not influence PBSC mobilization and autologous transplantation after 2 courses of FLAG.
